MedPath

Study on the effect of combination therapy of alpha-1 blocker and transdermal oxybutynin hydrochloride in patients with overactive bladder due to benign prostatic hyperplasia

Not Applicable
Conditions
Patients with overactive bladder due to benign prostatic hyperplasia
Registration Number
JPRN-UMIN000021414
Lead Sponsor
Department of Renal and Urologic Surgery, Asahikawa Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

Qmax on uroflowmetry 5ml/sec or less, postvoid residual urine 100ml or more, patients who underwent radiation to the prostate

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in total score of overactive bladder symptoms score(OABSS) 4weeks after the intervention
Secondary Outcome Measures
NameTimeMethod
Change in each item of OABSS 4weeks after the intervention Change in International Prostate Symptoms Score 4weeks after the intervention
© Copyright 2025. All Rights Reserved by MedPath